TY - JOUR
T1 - Sex-related incidence and survival differences in pediatric high-grade glioma subtypes
T2 - A population-based cohort study
AU - Hoogendijk, Raoull
AU - van der Lugt, Jasper
AU - Baugh, Josh
AU - Kline, Cassie
AU - Kranendonk, Mariette
AU - Hoving, Eelco
AU - Kremer, Leontien
AU - Wesseling, Pieter
AU - Karim-Kos, Henrike
AU - van Vuurden, Dannis
N1 - Funding Information: The authors would like to thank the registration team of the Netherlands Comprehensive Cancer Organization (IKNL) for the collection of data for the NCR and this project. Conceptualization, R.H. H.K.K. J.v.d.L. D.v.V.; Methodology, R.H. H.K.K. J.v.d.L. and D.v.V.; Formal Analysis, R.H.; Writing – R.H.; Writing – Review and Editing, All authors; Supervision, H.K.K. J.v.d.L. D.v.V. P.W. and E.H. The authors declare no competing interests. We support inclusive, diverse, and equitable conduct of research. Publisher Copyright: © 2023 The Author(s)
PY - 2023/10/20
Y1 - 2023/10/20
N2 - Not much is known on sex differences in incidence, survival, and treatment characteristics for midline and hemispheric pHGGs. This population-based study confirms previously reported study results that found worse survival outcomes for malignant diffuse gliomas in girls in the age group 0–9 years. Additionally, in our study we pinpoint this difference to girls with midline pHGGs aged 0–4 years. We provide insight in the possible underlying mechanisms contributing to sex survival differences in pHGG patients. With first line treatment having no impact on the higher risk of dying for girls, but age and tumor characteristics having a neutralizing effect. The results of this population-based study serve as a basis for future pre-clinical and clinical studies to further unravel the underlying mechanisms responsible for the survival gap between sexes in midline pHGG.
AB - Not much is known on sex differences in incidence, survival, and treatment characteristics for midline and hemispheric pHGGs. This population-based study confirms previously reported study results that found worse survival outcomes for malignant diffuse gliomas in girls in the age group 0–9 years. Additionally, in our study we pinpoint this difference to girls with midline pHGGs aged 0–4 years. We provide insight in the possible underlying mechanisms contributing to sex survival differences in pHGG patients. With first line treatment having no impact on the higher risk of dying for girls, but age and tumor characteristics having a neutralizing effect. The results of this population-based study serve as a basis for future pre-clinical and clinical studies to further unravel the underlying mechanisms responsible for the survival gap between sexes in midline pHGG.
KW - Cancer
KW - Pediatrics
KW - Population
KW - Public health
UR - http://www.scopus.com/inward/record.url?scp=85172250820&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.isci.2023.107957
DO - https://doi.org/10.1016/j.isci.2023.107957
M3 - Article
C2 - 37810231
SN - 2589-0042
VL - 26
JO - iScience
JF - iScience
IS - 10
M1 - 107957
ER -